Clinical Trial Update: A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating dapagliflozin in fatty liver disease; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Fatty Liver | Phase 3 | Status: UNKNOWN